IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Clinical trial NCT07122687 · RECRUITING

Trial details

NCT number: NCT07122687
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Start date: 2025-08-26
Primary completion: 2026-11-30
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.